Medicare Part D insurance tagged posts

Dar Walker
Executive Director of NAMI St. Louis

For nine years, Medicare beneficiaries have had access to the antidepressants and antipsychotics that work best for them. Now, a proposed change threatens to revoke that access. The resulting effect will be devastating for individuals with mental illness and their families, and costly to society at large.

It Doesn’t Add Up

Back in 2005, when the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Part D prescription drug benefit, it ensured patients would have unrestricted access to life-saving medicine by granting “protected-class” status to six drug categories, including antidepressants and antipsychotics.

In granting antidepressants and antipsychotics protected-class status, CMS acknowledged that these drugs are chemically distinct and not interchangeable, and patients must have access to the full category of drugs in order to appropriately manage their Illness. In 2010, the unique nature of mental health drugs was reaffirmed when the Affordable Care Act specified that the six protected classes should remain protected.

Read More

Dr. Scott Arbaugh
Faculty Member Washington University
Director, Geriatric Day Treatment Programs
Alton Memorial Hospital (Alton, IL), St. Joseph’s Hospital (Highland, IL) and St. Joseph’s Hospital (Breese, IL)

Speaking Up For the Silent Majority
How the proposed changes to Medicare Part D will harm middle-class seniors

As a geriatric psychiatrist in private practice, I see many middle-class patients. These are folks who have worked hard their whole lives and saved for their retirement; their homes and cars are paid for and they have a few dollars in the bank. Medicare covers the bulk of their healthcare expenses and many can afford some level of supplemental coverage.

Read More